Richard Chernaik
Internal Medicine · Bronx, NYNPI 1972521532
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 80 payments — averaging $119.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Otsuka America Pharmaceutical, Inc.$840
- AbbVie$726
- Teva Pharmaceuticals USA, Inc.$619
- Grifols USA, LLC$508
- Boehringer Ingelheim$500
- plus $4K from 22 others
What the payments were for
- Food & beverage$9,534100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 15 | $1,877 |
| Otsuka America Pharmaceutical, Inc. | 7 | $840 |
| AbbVie(2 entities) | 7 | $726 |
| Teva Pharmaceuticals USA, Inc. | 5 | $619 |
| Grifols USA, LLC | 5 | $508 |
| Boehringer Ingelheim | 4 | $500 |
| E.r. Squibb & Sons, L.L.C. | 3 | $395 |
| Novo Nordisk | 3 | $394 |
| Amgen | 3 | $375 |
| AstraZeneca | 3 | $369 |
| Lilly USA, LLC | 3 | $353 |
| Genentech USA, Inc. | 2 | $257 |
| Sanofi | 2 | $247 |
| Neurocrine Biosciences, Inc. | 2 | $244 |
| Gilead | 2 | $225 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $200 |
| Sequel Med Tech, LLC | 1 | $157 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $130 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Mallinckrodt Enterprises LLC | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Novartis | 1 | $122 |
| Bayer | 1 | $122 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $114 |
| Seagen Inc. | 1 | $111 |
| Abbott | 1 | $111 |
| Sanofi-aventis U.S. LLC | 1 | $98 |
| Merck | 1 | $75 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$957
- INVEGA SUSTENNA$675
- JARDIANCE$500
- ABILIFY MAINTENA$496
- Rinvoq$490
- COBENFY$395
- INVEGA TRINZA$394
- KISUNLA$353
- Ozempic$269
- UZEDY$250
- HyperRAB$250
- ABILIFY ASIMTUFII$250
- Prolia$250
- DUPIXENT$250
- AUSTEDO$247
- REXULTI$247
- INGREZZA$244
- TWIIST$157
- Xofluza$132
- CAPLYTA$130
How this compares
$9,541 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trazodone Hcl | 13 | $51 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Bronx
- Jason LeiderBronx$694K
- Bulent AtacBronx$647K
- Timothy KanterBronx$630K
- Shervin MortazaviBronx$374K
- Elizabeth Jenny-AvitalBronx$185K
- Meyer HalberstamBronx$143K
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.